Forecasts data is unavailable for this security.

Consensus recommendation

As of Jan 14, 2017, the consensus forecast amongst 29 polled investment analysts covering AstraZeneca plc advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts improved on Jan 20, 2016. The previous consensus forecast advised investors to hold their position in AstraZeneca plc.
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.


In 2015, AstraZeneca PLC reported a dividend of 2.80 USD, equaling last years dividend. The 30 analysts covering the company expect dividends of 2.77 USD for the upcoming fiscal year, a decrease of 1.25%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates

On Nov 10, 2016, AstraZeneca plc reported 3rd quarter 2016 earnings of 1.32 per share. This result exceeded the 0.97 consensus of the 18 analysts covering the company and exceeded last year's 3rd quarter results by 28.16%.
The next earnings announcement is expected on Feb 02, 2017.
Average growth rate+9.68%
AstraZeneca plc reported annual 2015 earnings of 4.26 per share on Feb 04, 2016.
The next earnings announcement from AstraZeneca plc is expected the week of Feb 02, 2017.
Average growth rate-12.22%
More ▼

Revenue history & estimates

AstraZeneca PLC had 3rd quarter 2016 revenues of 5.70bn. This missed the 5.87bn consensus estimate of the 18 analysts following the company. This was 4.14% below the prior year's 3rd quarter results.
Average growth rate-0.93%
AstraZeneca PLC had revenues for the full year 2015 of 23.64bn. This was 9.40% below the prior year's results.
Average growth rate-8.18%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.